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Abstract
Introduction: Preventing unintended pregnancies is important among all women, including those living with HIV. Increasing
numbers of women, including HIV-positive women, choose progestin-containing subdermal implants, which are one of the
most effective forms of contraception. However, drug–drug interactions between contraceptive hormones and efavirenz-
based antiretroviral therapy (ART) may reduce implant effectiveness. We present four inter-related perspectives on this
issue.
Discussion: First, as a case study, we discuss how limited data prompted country-level guidance against the use of implants
among women concomitantly using efavirenz in South Africa and its subsequent negative effects on the use of implants in
general. Second, we discuss the existing clinical data on this topic, including the observational study from Kenya showing
women using implants plus efavirenz-based ART had three-fold higher rates of pregnancy than women using implants plus
nevirapine-based ART. However, the higher rates of pregnancy in the implant plus efavirenz group were still lower than the
pregnancy rates among women using common alternative contraceptive methods, such as injectables. Third, we discuss the
four pharmacokinetic studies that show 50–70% reductions in plasma progestin concentrations in women concurrently using
efavirenz-based ART as compared to women not on any ART. These pharmacokinetic studies provide the biologic basis for
the clinical findings. Fourth, we discuss how data on this topic have marked implications for both family planning and HIV
programmes and policies globally.
Conclusion: This controversy underlines the importance of integrating family planning services into routine HIV care,
counselling women appropriately on increased risk of pregnancy with concomitant implant and efavirenz use, and expanding
contraceptive method mix for all women. As global access to ART expands, greater research is needed to explore implant
effectiveness when used concomitantly with newer ART regimens. Data on how HIV-positive women and their partners
choose contraceptives, as well as information from providers on how they present and counsel patients on contraceptive
options are needed to help guide policy and service delivery. Lastly, greater collaboration between HIV and reproductive
health experts at all levels are needed to develop successful strategies to ensure the best HIV and reproductive health
outcomes for women living with HIV.
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Introduction
Up to 62% of pregnancies among women living with HIV in
sub-Saharan Africa are unintended, contributing to HIV-
related maternal morbidity and vertical HIV transmission
[1–8]. Modern contraception, including hormonal and non-
hormonal contraceptives, can help prevent unintended
pregnancies. Paralleling a global shift, a marked increase
in modern contraceptive prevalence has occurred in sub-
Saharan African in recent decades, with average prevalence
ranging from 8% in the 1980s to 22% in 2010 [9,10]. Long-
acting reversible contraception (LARC), including progestin-
containing subdermal implants and intrauterine devices
(IUDs), are preferred by the World Health Organization
(WHO) [11], and implants are the most effective LARC
with increasing use in sub-Saharan Africa, including among
HIV-positive women [9,10,12–14].
Though the expected contraceptive failure rate with
implants is below 1% [15–19], drug–drug interactions
between implants and antiretroviral therapy (ART), particu-
larly efavirenz-based ART, may compromise implant effec-
tiveness. Implant progestins, etonogestrel and
levonorgestre, are metabolized by a hepatic cytochrome
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P450 enzyme, and efavirenz, a non-nucleoside reverse tran-
scriptase inhibitor (NNRTI), is a potent inducer of this
enzyme. Therefore, reduced implant effectiveness is
thought to be related to lower systemic progestin concen-
trations [20,21]. This issue is particularly important because
efavirenz-based ART remains the recommended first-line
regimen by the WHO [22].
Below we present four inter-related perspectives on this
issue. The first perspective examines a case study of how,
based on limited data, authorities in South Africa recom-
mended against the use of implants for women concomi-
tantly using efavirenz, and how this policy led to
unintended negative consequences. The second and third
perspectives summarize the current clinical and pharmaco-
kinetic (PK) data regarding concomitant implant and efavir-
enz-based ART use. The final perspective discusses the
global implications of these findings for family planning
and HIV programmes. We conclude with specific research
recommendations that will aid providers and policy makers
in helping HIV-positive women actualize their reproductive
intentions with appropriate information, while maintaining
options for highly effective family planning alongside ART.
Discussion
A case study: impact of country-specific guidance
recommending against the use of implants for women
prescribed efavirenz-based ART in South Africa
The implant was introduced into South Africa in early 2014,
as part of a major revision of South Africa’s contraceptive
guidelines, including an expanded contraceptive method
mix that emphasizes LARC. By the start of 2015, nearly
900,000 implants had been inserted [23].
The 2012 National Contraceptive Guidelines advised that,
despite potential drug–drug interactions between implants
and certain ART, implants could be used by all ART users,
particularly with concurrent condom use for enhanced
pregnancy protection. In October 2014, emerging PK [24]
and clinical pregnancy [25] data, coupled with reported
implant failure among efavirenz users in South Africa, led
the national Essential Medicines List Committee to change
prescribing guidelines to: “women who are taking enzyme
inducing drugs [such as efavirenz]…should not use proges-
tin subdermal implants” [26]. This guidance was expanded
upon in December 2014 allowing for continued concomi-
tant implant and efavirenz use among women with an
implant already inserted, “if the woman has been properly
counseled” [27].
This guidance was intended to urgently inform providers
about the possibility of decreased implant effectiveness
when combined with efavirenz. However, an ongoing qua-
litative study in Western Cape Province, conducted by one
of the co-authors (C.M.), revealed discontinuation of
implant provision to most HIV-positive women, regardless
of ART regimen, implant removals among women on efa-
virenz-based ART, and lack of support for efavirenz users
who continued implant use. This study has documented
several provider concerns, including risk of implant inser-
tion in all HIV-positive women in case of future ART need,
lack of providers’ understanding of specific drug–drug inter-
actions, provider uncertainty in communicating this infor-
mation to their patients, and a sense of clinical and legal
vulnerability among the providers for potential implant fail-
ures. These results suggest that implants could be inadver-
tently removed as a contraceptive option for HIV-positive
women in South Africa. In light of such unintended con-
sequences, in the next two sections, we will review the
current clinical and PK data, respectively, to more compre-
hensively understand the risk of implant failures with con-
comitant efavirenz-based ART use.
Clinical data on contraceptive failures with concomitant
implant and efavirenz use
Initially, case reports raised concerns of contraceptive fail-
ure when implants were combined with efavirenz-based
ART [28–31]. The first clinical study of etonogestrel
implants in Brazil found no pregnancies in the 20 women
on efavirenz-based ART after three years of follow-up [32].
The second clinical study from Swaziland, a retrospective
chart review of 332 ART users on levonorgestrel implants
found that 15 (12.4%) of 121 women on efavirenz-based
ART became pregnant in comparison to no pregnancies in
the non-efavirenz-based ART groups [25]. The third clinical
study combined data from three longitudinal studies and
found that among implant users, the rate of incident preg-
nancy was 6.0 vs. 1.4 pregnancies/100 women-years in
women using efavirenz-based ART vs. no ART, respec-
tively [33].
Finally, a 3-year retrospective cohort study from Kenya
examined pregnancy rates among nearly 25,000 HIV-
positive women reporting use of various combinations of
contraceptive methods and ART regimens [34]. Among
implant users, they found the adjusted pregnancy rate
was 3.3 per 100 women-years with efavirenz-based ART,
compared with 1.1 with nevirapine-based ART and 1.3 with
no ART. In other words, among women using implants,
those using efavirenz-based ART had three-fold higher
pregnancy rates than women using nevirapine-based ART
(95% CI 1.3–4.6). However, this study also showed that
among efavirenz-based ART users, women reporting use
of oral and injectable contraceptives were up to three
times more likely to become pregnant than those reporting
use of implants (adjusted pregnancy rate ratio of 2.8
(0.97–4.7) and 1.6 (0.83–2.5), respectively). Hence, the
Kenya study suggests that despite drug–drug interactions,
implants remain more or as effective than oral and inject-
able contraceptives among HIV-positive women using
efavirenz.
The cohort studies each have unique limitations, such as
self-reported contraceptive use or a small sample size. The
study from Brazil was limited by a small sample size, follow-
up every 6 months potentially leading to missed early
pregnancy loss, low adherence to ART, and lack of clarity
of how many participants reached the 3-year end point.
Several limitations affected the Kenyan study, which offers
the most comprehensive data on this topic. First, since
contraceptive use was self-reported, social desirability for
using contraception and difficulties discussing fertility
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intentions with providers may have led women to more
often report contraceptive use, particularly methods such
as injectables that could not be verified by
providers. Second, pregnancy was diagnosed clinically,
thus potentially leading to underreported early gestation
pregnancy loss. Last, though the authors adjusted for con-
current condom use, other potential confounders, such as
adherence to both contraceptive method and ART and
sexual activity could not be adjusted for in this current
analysis.
Future prospective studies that include frequent ascer-
tainment and independent verification of contraceptive
use, ART regimens, and pregnancy can overcome the lim-
itations of the existing cohort studies. However, such pro-
spective studies will require long periods of follow-up and
be costly. Therefore, a role remains for efficiently combin-
ing findings from PK studies with secondary analyses of
routinely collected clinical data. As such, in the next sec-
tion, we elaborate on the existing PK evidence regarding
concomitant implant and efavirenz use.
PK of implant progestins in combination with
efavirenz-based ART
Pharmacologic evidence to support the biologic basis for
reduced effectiveness of implants in women on efavirenz
has emerged from four recent PK studies. Three prospec-
tive studies inserted implants at study entry and com-
pared plasma progestin concentrations in women
receiving efavirenz-based ART to a similar group of HIV-
positive women not receiving ART (control group). The
first study assessed etonogestrel PK for 24 weeks after
implant insertion (n = 14 per group) [24,35]. At week 24,
etonogestrel concentrations were 70% lower in the efavir-
enz group, compared to the control group (69 vs. 230 pg/
mL; p < 0.001). Luteal activity, a surrogate marker of the
ability to become pregnant, occurred in 2.8–5% of parti-
cipants receiving efavirenz compared to no subject in the
control group (p < 0.05). A similar study was conducted in
Uganda that described levonorgestrel PK over 48 weeks
(n = 20 per group) [35,36]. At week 48, levonorgestrel
concentrations were 57% lower in the efavirenz group,
compared to the control group (247 vs. 580 pg/mL;
p < 0.001). Between study weeks 36 and 48, three
women (15%) in the efavirenz group became pregnant.
No pregnancy occurred in the control group. Another
study in Uganda found 82% lower etonogestrel concentra-
tions after 24 weeks of the implant plus efavirenz-based
ART in 19 women compared to 20 women in the control
group (66 vs. 362 pg/mL, p < 0.001); all women receiving
efavirenz in this study also had a copper IUD in place, so
no pregnancies were observed [37]. In addition to these
prospective cohorts, one cross-sectional study evaluated
etonogestrel concentrations 6–7 weeks after implant
insertion in women receiving efavirenz- (n = 9) or pro-
tease inhibitor-based ART (n = 45) [38]. Women receiving
efavirenz had >90% lower etonogestrel concentrations
(41.5 pg/mL) compared to those receiving protease inhi-
bitors. In addition, the authors report one pregnancy
(11%) 16 months after implant insertion in a woman
receiving efavirenz.
Overall, these PK results for efavirenz plus implant pro-
gestins are consistent with efavirenz-progestin interactions
observed with oral and transdermal routes of contraceptive
administration [20]. Notably, nevirapine, another NNRTI,
did not adversely influence implant progestin exposure
[20,37]. These results are consistent with reports of nevir-
apine plus oral progestins [20], suggesting that nevirapine
has less potent cytochrome P450 enzyme induction than
efavirenz. Finally, the effect of lopinavir/ritonavir and ata-
zanavir/ritonavir on etonogestrel were evaluated in two of
the studies [24,38] and higher progestin exposure was
observed without excess adverse events, suggesting that
contraceptive implants are not adversely effected by pro-
tease inhibitors.
While assessing drug concentrations is a standard
approach to measure the expected influence of drug–drug
interactions on clinical outcomes [39], the implant PK stu-
dies to date were not designed to concurrently evaluate
contraceptive effectiveness. In addition, these were non-
randomized, observational studies, due to the clinical
necessity of ART initiation and long follow-up required to
characterize implant progestin PK. Despite these limita-
tions, three of the four studies directly observed pregnan-
cies, a clinically significant outcome. Further, the proposed
implant progestin PK threshold for contraceptive effective-
ness is based on few cases of observed pregnancies. For
example, 180 pg/mL was previously suggested as the
desired levonorgestrel threshold based on five pregnancies
in women receiving the implant for longer than its intended
duration of use [40]. In contrast, two of the three pregnan-
cies observed in the Ugandan study occurred above this
threshold (297 and 303 pg/mL) [35]. This may be related to
the anticipated variability when observing few cases or due
to different laboratory methodologies. Nonetheless, the
current PK data are consistent with each other and the
clinical data. Future PK studies also investigating measures
of contraceptive effectiveness, such as cervicovaginal
mucus or ovulation, may help better establish thresholds
for contraceptive effectiveness; however, such studies will
be time and resource intensive, again highlighting the
importance of combining clinical and PK data.
Implications for global family planning and HIV
programmes and policies
In light of the clinical and PK data, we now examine the
implications of such data for family planning and HIV pro-
grammes and policies globally, given the growing popula-
tion of women using concomitant contraceptive implants
and ART. First, integrating family planning services into
existing HIV platforms provides an important opportunity
to reach providers and women with information about how
these medications may interact. This provides women the
opportunity to obtain counselling with the same provider
for both her family planning and HIV needs, streamlining
holistic care for the women.
Second, an implant being a more effective method than
other hormonal methods when used concomitantly with
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efavirenz does not negate the fact that implants are failing
for some women. HIV-positive women considering implants
should be informed about the possibility of the implant’s
decreased effectiveness with concomitant efavirenz use.
Counselling on the potential risks of failure is essential to
ensure that women can consider other effective methods,
and if they choose implants, recognize signs of early preg-
nancy. Nonetheless, women should retain the right to make
an informed decision and still choose implants after weigh-
ing the risks and benefits of available methods.
Last, the challenge of concomitant implant and efavirenz
use highlights the necessity of a robust contraceptive
method mix, which includes more choices for LARC. For
example, non-hormonal IUDs could be a potential alterna-
tive to implants. However, persistent challenges to optimiz-
ing method mix include method cost, provider preferences,
lack of trained staff, weak logistics and supply manage-
ment, lack of demand for certain methods, and misinfor-
mation. Donor and country partners are supporting efforts
to address these challenges and provide a range of com-
modities to ensure HIV-positive women have a real choice
when weighing contraceptive risks and benefits relevant for
their lives.
Conclusions
As global access to ART expands, there are critical gaps in
evidence to support the combination of implants with
newer ART regimens. Existing clinical data indicate reduced
contraceptive effectiveness when implants and efavirenz
are used concomitantly, though the implants still remain
more effective at preventing pregnancy than most alterna-
tive hormonal contraceptive methods. PK studies that find
significantly reduced levonorgestrel and etonogestrel con-
centrations when used with efavirenz demonstrate the
biologic mechanism of reduced implant efficacy. While PK
and clinical data may support the combination of nevira-
pine [35,37], atazanavir/ritonavir- [38,41], or lopinavir/rito-
navir-based ART [24,38] with implants, these regimens are
not recommended as first-line regimens for HIV treatment
due to issues of side effects or resistance profiles [42–45].
Research on the combination of implants with newer ART
regimens, such as dolutegravir-based ART, could provide
critical information prior to or during early rollout of new
treatment guidelines.
Efavirenz-based ART will continue to be a first-line regimen
in most resource-limited settings for the foreseeable future,
particularly in combination with anti-tuberculosis treatments.
Therefore, data to support alternative strategies for optimiz-
ing the effectiveness of contraceptive implants in combina-
tion with efavirenz-based ART are urgently needed. Such
strategies could include increasing the implant dose to main-
tain blood concentrations above a threshold of efficacy or
decreasing the length of implant use if failures are related to
increasing duration of implant use. Data regarding the influ-
ence of reducing the efavirenz dose from 600 mg to 400 mg/
day on contraceptive hormone drug–drug interactions are
also urgently needed.
Finally, a single, cross-over, PK study with short-term oral
contraceptives in healthy subjects are currently required by
regulatory authorities, such as the United States Food and
Drug Administration, to characterize a new drug’s impact on
hormonal contraceptive exposure. This scenario with implants
and efavirenz could have been identified and addressed earlier
if pharmaceutical companies were required to conduct more
comprehensive PK testing with several hormonal contracep-
tive methods, given the diversity of hormonal contraceptive
hormones and routes of administration. Finally, simply provid-
ing impractical statements that barrier methods should always
be used in conjunction with hormonal contraception does not
provide appropriate options for women living with HIV [46].
Ultimately, greater collaboration between HIV and repro-
ductive health experts at all levels are needed to develop
successful strategies to ensure the best HIV and reproductive
health outcomes for women living with HIV. South Africa’s
guidance implementation provides important lessons on why
collaboration is essential. To facilitate this, information on
values and preferences with respect to how HIV-positive
women and their partners choose contraceptives, as well
information from providers on how they present and counsel
on contraceptive options are needed to help guide policy and
service implementation. A focus on developing appropriate
information and counselling tools to support providers and
HIV-positive women is needed to avoid blanket guidance
against concomitant implant and efavirenz use. Finally, using
a rights-based approach to this issue can help ensure all
women living with HIV are able to choose a contraceptive
method that is best suited for their lives from among a range
of options.
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